A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced ...
MedPage Today on MSN
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Tweaked lipid nanoparticle delivery system showed early safety ...
A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62 ...
Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve ...
NEW YORK (Reuters Health) - People with diabetes, coronary heart disease, and chronic kidney disease benefit from having their cholesterol levels lowered aggressively with high doses of Lipitor, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results